243 related articles for article (PubMed ID: 36926051)
1. HR
Torrisi R; Jacobs F; Miggiano C; De Sanctis R; Santoro A
Drugs Context; 2023; 12():. PubMed ID: 36926051
[TBL] [Abstract][Full Text] [Related]
2. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
3. Genomic Characterization of
Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
5. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
Seltzer S; Corrigan M; O'Reilly S
Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
7. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Müller V; Hein A; Hartkopf AD; Fasching PA; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Beckmann MW; Schneeweiss A; Belleville E; Uhrig S; Wimberger P; Hielscher C; Meyer J; Wurmthaler LA; Kurbacher CM; Wuerstlein R; Untch M; Janni W; Taran FA; Lux MP; Wallwiener D; Brucker SY; Fehm TN; Michel LL
Eur J Cancer; 2022 Sep; 172():13-21. PubMed ID: 35728342
[TBL] [Abstract][Full Text] [Related]
8.
Lord SJ; Bahlmann K; O'Connell DL; Kiely BE; Daniels B; Pearson SA; Beith J; Bulsara MK; Houssami N
EClinicalMedicine; 2022 Feb; 44():101282. PubMed ID: 35128368
[TBL] [Abstract][Full Text] [Related]
9. Use and results of systemic treatments for de novo and recurrent metastatic breast cancer: a population-based cohort study.
Lao C; Kuper-Hommel M; Campbell I; Elwood M; Lawrenson R
N Z Med J; 2021 Nov; 134(1545):47-59. PubMed ID: 34788271
[TBL] [Abstract][Full Text] [Related]
10. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of De Novo Metastatic Breast Cancer.
Daily K; Douglas E; Romitti PA; Thomas A
Clin Breast Cancer; 2021 Aug; 21(4):302-308. PubMed ID: 33750642
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
13. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients.
Wang J; Liu Y; Liang Y; Zhang Y; Dong H; Zheng T; Yu J; Du P; Jia S; King BL; Wang J; Liu X; Li H
Front Oncol; 2023; 13():1152575. PubMed ID: 37361577
[TBL] [Abstract][Full Text] [Related]
15. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
Gilbert A; Williams C; Azuero A; Burkard ME; Kenzik K; Garrett-Mayer E; Meersman S; Rocque G
Clin Breast Cancer; 2021 Aug; 21(4):292-301. PubMed ID: 33309481
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
17. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
[TBL] [Abstract][Full Text] [Related]
18. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group.
Dogan I; Aksoy S; Cakar B; Basaran G; Ercelep O; Molinas Mandel N; Korkmaz T; Gokmen E; Sener C; Aydiner A; Saip P; Eralp Y
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980554
[TBL] [Abstract][Full Text] [Related]
19. Aggressive local therapy for
Liu B; Liu H; Liu M
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449542
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
